Lakeside Holding (LSH) investor relations material

Company overview and business model

• Focused on pharmaceutical distribution in China through Hupan Pharmaceutical, serving hospitals and healthcare providers with infusion products, specialty pharmaceuticals, and foods for special medical purposes.

• Recently divested U.S.-based logistics operations to concentrate resources on pharmaceutical distribution and explore quantum-enabled AI and post-quantum cryptography through Quantum Nexus Technologies Ltd.

• Evaluating expansion into digital asset business activities, though no concrete operational plans or revenue from these initiatives as of the filing date.

• Operates primarily in the midstream pharmaceutical supply chain, sourcing from manufacturers and distributing to hospitals and distributors, with sales conducted mainly through agents.

• Substantially all business is conducted through the PRC subsidiary, exposing the company to significant regulatory and operational risks associated with Chinese government oversight.

Financial performance and metrics

• As of August 4, 2026, public float was approximately $21.98 million, with 31,726,959 shares held by non-affiliates out of 34,427,559 total shares at a closing price of $0.6928 per share.

• No securities sold under General Instruction I.B.6 of Form S-3 in the prior 12 months; subject to the Baby Shelf Limitation, restricting primary offerings to no more than one-third of public float in any 12-month period if public float remains below $75 million.

• Revenue is derived from over 55 customers, with about five accounting for more than 10% of total revenue each in the past three fiscal quarters ended March 31, 2026.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement for each offering.